Aptamer Group PLC shares climbed on Wednesday as it said it has won a £360,000 service contract with an unnamed ‘top 3 global pharmaceutical company’.
The York, England-based synthetic binders developer said the fee-for-service development contract is to develop Optimer binders as targeted radiopharmaceuticals, with potential applications in therapeutics.
Aptamer said it retains rights for future licensing revenue upon commercialisation under the deal.
Shares in Aptamer jumped 17% to 1.11 pence in London on Wednesday afternoon.
The programme will engineer Optimers to target an undisclosed cancer target.
Aptamer said it has secured £315,000 in new contracts and project extensions for the current financial year.
‘These developments further position the company for revenue growth in the current year,’ it said.
Including the new development contract, Aptamer said it has secured additional commitments worth £675,000 in total contract value.
Combined with £350,000 carried over from financial 2025, this provides £1.0 million in contract value for the current period, with nine months of the year remaining.
The firm said its sales pipeline ‘remains robust and healthy’ and now stands at £3.4 million for fee-for-service opportunities.
However, Aptamer is not providing formal guidance for financial 2026 at this stage as contract timings, project completions and revenue recognition ‘can vary significantly’ across quarters.
‘This significant contract win with a top 3 global pharmaceutical company marks a key expansion of our platform into targeted radiopharmaceuticals and potential therapeutics,’ said Chief Executive Officer Arron Tolley.
‘This represents a value inflection point as Aptamer now has two potential therapeutic assets under development.’
Copyright 2025 Alliance News Ltd. All Rights Reserved.